News from royalty pharma A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 05, 2020, 16:15 ET Royalty Pharma Acquires Royalties on Entyvio® from Massachusetts General Hospital

Royalty Pharma announced today that it has acquired Massachusetts General Hospital's (MGH) royalty interest in Entyvio (vedolizumab) for $94 million. ...

Feb 28, 2020, 08:55 ET Christopher Hite Joins Royalty Pharma

Royalty Pharma announced today that Chris Hite has agreed to join the Company as Executive Vice President and Vice Chairman. Chris joined Citi as...

Jan 31, 2020, 09:00 ET Royalty Pharma Announces Appointment of George Grofik as SVP, Head of Investor Relations and Communications

Royalty Pharma, the largest acquiror of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry,...

Nov 05, 2019, 08:00 ET Royalty Pharma Announces Agreement to Purchase Future Royalties on Tazemetostat from Eisai for $330 Million and a $100 Million Initial Investment in Epizyme

Royalty Pharma announced today that it has agreed to pay $330 million to purchase Eisai Co., Ltd.'s royalties on future worldwide sales of...

Apr 01, 2019, 05:00 ET Arteaus Therapeutics Sells Emgality Royalty to Royalty Pharma for $260 Million

Royalty Pharma and Arteaus Therapeutics, a biotechnology development company co-founded by Atlas Venture and OrbiMed, announced today that Arteaus...

Dec 03, 2018, 12:30 ET Royalty Pharma Announces Promotions in Finance Team in Anticipation of Next Growth Phase

Royalty Pharma is pleased to announce that Susannah Gray has been named Executive Vice President – Finance & Strategy, Terrance Coyne has been...

Mar 04, 2016, 10:30 ET UCLA sells royalty rights connected with cancer drug to Royalty Pharma for $1.14 billion

UCLA and Royalty Pharma announced today that UCLA has sold its royalty interest connected with a leading prostate cancer medication, Xtandi, whose...

Feb 12, 2015, 08:30 ET Royalty Pharma Announces George Lloyd is Named General Counsel

Royalty Pharma is pleased to announce that George Lloyd has been named General Counsel of Royalty Pharma effective immediately. Since joining Royalty ...

Jan 15, 2015, 11:30 ET Royalty Pharma Announces Greg Norden Joins Investment Committee

Royalty Pharma is pleased to announce that Greg Norden has joined its Investment Committee. Greg brings more than 25 years of leadership experience...

Nov 19, 2014, 07:22 ET Royalty Pharma Announces $3.3 Billion Royalty Transaction with Cystic Fibrosis Foundation Therapeutics

Royalty Pharma announced today its acquisition of royalties on Vertex Pharmaceuticals' cystic fibrosis treatments owned by Cystic Fibrosis Foundation ...

Jan 06, 2014, 08:00 ET Royalty Pharma Acquires Additional Interest in TECFIDERA® for $510 Million

Royalty Pharma announced today that it has acquired an additional interest in the earn-out payable to the former shareholders of Fumapharm AG for...

Aug 12, 2013, 07:00 ET Royalty Pharma Partners with Aisling Capital and Clarus Ventures in Recent Ibrutinib Royalty Purchase

Royalty Pharma announced today that, pursuant to a collaboration with Aisling Capital and Clarus Ventures, it has sold to Aisling and Clarus...

Jul 19, 2013, 08:00 ET Royalty Pharma Announces Marshall Urist, MD, PhD, Joins Management Team

Royalty Pharma is pleased to announce that Marshall Urist, MD, PhD, has joined the company as Vice President, Research and Investments. Dr. Urist...

Jun 18, 2013, 06:43 ET Royalty Pharma Announces Withdrawal Of Judicial Review And Lapse Of Offer

Royalty Pharma announced today that it had withdrawn its request for a judicial review of the Irish Takeover Panel's decision requiring it to lapse...

Jun 17, 2013, 10:31 ET Royalty Pharma Informs Elan Stockholders About The Consequences Arising From The Results Of The Elan EGM Earlier Today

As the Share Repurchase Resolution has been passed at the Elan EGM earlier today, Royalty Pharma's Offer for Elan Corporation, plc (NYSE: ELN) has...

Jun 17, 2013, 02:26 ET Royalty Pharma Chairman Writes Open Letter to Elan Board

Royalty Pharma announced today that Rory Riggs, Chairman and Co-Founder of the Royalty Pharma group, is sending the following open letter to the...

Jun 14, 2013, 01:41 ET Elan ADS Holders Decisively Vote Against Theravance And AOP Transactions

Royalty Pharma today announces that as of 3:00 pm EDT on Thursday, June 13, 2013 holders of approximately 311 million Elan ADSs, representing more...

Jun 14, 2013, 01:34 ET Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty

Royalty Pharma notes today's announcement by Elan Corporation, plc (NYSE: ELN) that it intends to explore a sale of the Company. Royalty Pharma...

Jun 13, 2013, 07:53 ET Royalty Pharma Announces Offer May Lapse (Be Withdrawn)

Royalty Pharma today announces that as of 5:30 pm EDT on Wednesday, June 12, 2013 holders of approximately 276 million Elan ADSs (NYSE: ELN),...

Jun 11, 2013, 11:24 ET In Royalty Pharma's View, Elan's EGM Circular is Misleading and Omits Key Information that Elan Shareholders Need to Make an Informed Decision

Royalty Pharma today announced that it believes Elan's (NYSE: ELN) disclosure in its May 27 EGM Circular is misleading and inadequate, in Royalty...

Jun 11, 2013, 08:55 ET Royalty Pharma Statement Regarding Withdrawal of Elan Lawsuit

Royalty Pharma announced today that Elan voluntarily withdrew the lawsuit it had filed on an expedited basis only one week ago in New York federal...

Jun 11, 2013, 02:25 ET Royalty Pharma Files Judicial Review Proceedings

Royalty Pharma today announces that it has reluctantly filed judicial review proceedings related to the decision of the Irish Takeover Panel...

Jun 11, 2013, 02:07 ET Royalty Pharma Acceptances Announcement

In accordance with Rule 17.1 and Rule 2.9 of the Irish Takeover Rules and Rule 14e-1 of the US Exchange Act, Echo Pharma Acquisition Limited...

Jun 10, 2013, 06:46 ET Royalty Pharma Statement Regarding Withdrawal of Elan Lawsuit

Royalty Pharma announced today that Elan voluntarily withdrew the lawsuit it had filed on an expedited basis only one week ago in New York federal...

Jun 10, 2013, 06:33 ET Royalty Pharma Urges Elan Shareholders to Vote AGAINST ALL FOUR Elan Resolutions Today

Royalty Pharma today urged Elan Corporation, plc (NYSE: ELN) Shareholders to immediately vote AGAINST ALL FOUR resolutions Elan's Board has put forth ...